JP2014515743A - Ｔｇｆ−アルファおよびエピレグリンに結合する抗体 - Google Patents

Ｔｇｆ−アルファおよびエピレグリンに結合する抗体 Download PDF

Info

Publication number
JP2014515743A
JP2014515743A JP2014503684A JP2014503684A JP2014515743A JP 2014515743 A JP2014515743 A JP 2014515743A JP 2014503684 A JP2014503684 A JP 2014503684A JP 2014503684 A JP2014503684 A JP 2014503684A JP 2014515743 A JP2014515743 A JP 2014515743A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
alpha
epiregulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014503684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515743A5 (https=
Inventor
キャサリン・ブラウティガム・ベイドラー
ジョゼフ・ジョージ・ヒューアー
ラモナ・ユディタ・ペトロヴァン
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2014515743A publication Critical patent/JP2014515743A/ja
Publication of JP2014515743A5 publication Critical patent/JP2014515743A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014503684A 2011-04-06 2012-03-28 Ｔｇｆ−アルファおよびエピレグリンに結合する抗体 Ceased JP2014515743A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472338P 2011-04-06 2011-04-06
US61/472,338 2011-04-06
PCT/US2012/030802 WO2012138510A1 (en) 2011-04-06 2012-03-28 Antibodies that bind tgf-alpha and epiregulin

Publications (2)

Publication Number Publication Date
JP2014515743A true JP2014515743A (ja) 2014-07-03
JP2014515743A5 JP2014515743A5 (https=) 2015-05-14

Family

ID=45929050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014503684A Ceased JP2014515743A (ja) 2011-04-06 2012-03-28 Ｔｇｆ−アルファおよびエピレグリンに結合する抗体

Country Status (26)

Country Link
US (1) US8613921B2 (https=)
EP (1) EP2694547B1 (https=)
JP (1) JP2014515743A (https=)
KR (1) KR101581517B1 (https=)
CN (1) CN103459423B (https=)
AR (2) AR085484A1 (https=)
AU (1) AU2012240508B2 (https=)
BR (1) BR112013023513A2 (https=)
CA (1) CA2832256C (https=)
CY (1) CY1116332T1 (https=)
DK (1) DK2694547T3 (https=)
EA (1) EA024921B1 (https=)
ES (1) ES2539503T3 (https=)
HR (1) HRP20150468T1 (https=)
IL (1) IL228101A0 (https=)
ME (1) ME02063B (https=)
MX (1) MX2013011596A (https=)
PL (1) PL2694547T3 (https=)
PT (1) PT2694547E (https=)
RS (1) RS54000B1 (https=)
SG (1) SG193452A1 (https=)
SI (1) SI2694547T1 (https=)
TW (1) TWI454481B (https=)
UA (1) UA110051C2 (https=)
WO (1) WO2012138510A1 (https=)
ZA (1) ZA201306813B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532287A (ja) * 2020-06-26 2023-07-27 イーライ リリー アンド カンパニー 疼痛の治療における使用のためのＴＧＦ－α及びエピレグリンに結合する抗体

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
KR102495473B1 (ko) * 2020-10-06 2023-02-06 서울대학교병원 앰피레귤린을 유효성분으로 포함하는 안질환 치료용 조성물
AR125902A1 (es) 2021-05-21 2023-08-23 Lilly Co Eli Compuestos y métodos dirigidos a epirregulina

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010137654A1 (ja) * 2009-05-29 2010-12-02 株式会社未来創薬研究所 Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190858A (en) 1989-02-01 1993-03-02 Oncogene Science, Inc. Monoclonal antibodies directed to epitopes of human transforming growth factor--α and uses thereof
CA2683109A1 (en) 2006-10-11 2008-04-17 Fusion Antibodies Limited Combination therapy
MY162056A (en) * 2006-10-12 2017-05-31 Univ Tokyo Diagnosis and treatment of cancer using anti -ereg antibody
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010137654A1 (ja) * 2009-05-29 2010-12-02 株式会社未来創薬研究所 Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532287A (ja) * 2020-06-26 2023-07-27 イーライ リリー アンド カンパニー 疼痛の治療における使用のためのＴＧＦ－α及びエピレグリンに結合する抗体
JP7558306B2 (ja) 2020-06-26 2024-09-30 イーライ リリー アンド カンパニー 疼痛の治療における使用のためのＴＧＦ－α及びエピレグリンに結合する抗体

Also Published As

Publication number Publication date
AR123912A2 (es) 2023-01-25
CA2832256C (en) 2016-02-09
SI2694547T1 (sl) 2015-05-29
HRP20150468T1 (hr) 2015-06-05
ZA201306813B (en) 2015-04-29
AU2012240508B2 (en) 2014-10-23
ME02063B (me) 2015-05-20
US20120258109A1 (en) 2012-10-11
TWI454481B (zh) 2014-10-01
TW201300414A (zh) 2013-01-01
RS54000B1 (sr) 2015-10-30
ES2539503T3 (es) 2015-07-01
PT2694547E (pt) 2015-06-01
KR20130133274A (ko) 2013-12-06
CY1116332T1 (el) 2017-02-08
HK1190410A1 (en) 2014-07-04
SG193452A1 (en) 2013-10-30
NZ614198A (en) 2015-09-25
AR085484A1 (es) 2013-10-02
AU2012240508A1 (en) 2013-08-29
WO2012138510A1 (en) 2012-10-11
UA110051C2 (uk) 2015-11-10
BR112013023513A2 (pt) 2016-11-22
CA2832256A1 (en) 2012-10-11
IL228101A0 (en) 2013-09-30
CN103459423A (zh) 2013-12-18
KR101581517B1 (ko) 2015-12-30
EA024921B1 (ru) 2016-11-30
PL2694547T3 (pl) 2015-08-31
CN103459423B (zh) 2016-03-02
MX2013011596A (es) 2013-12-09
EP2694547A1 (en) 2014-02-12
DK2694547T3 (en) 2015-04-27
EA201370196A1 (ru) 2014-02-28
US8613921B2 (en) 2013-12-24
EP2694547B1 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
CN109863173B (zh) 抗-il-33抗体及其用途
JP6193871B2 (ja) 慢性若しくは急性疾患又は急性病態に罹患している患者の臓器機能障害又は臓器不全を予防又は軽減するための、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
JP7271430B2 (ja) 抗ｘｉ因子抗体
WO2020259605A1 (zh) 包含抗cd47/pd-l1双特异性抗体的制剂及其制备方法和用途
US9670284B2 (en) Therapeutic uses for VEGFR1 antibodies
CN102481340A (zh) 干细胞靶向
JP7558306B2 (ja) 疼痛の治療における使用のためのＴＧＦ－α及びエピレグリンに結合する抗体
TWI454481B (zh) 結合ＴＧＦ－α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體
NZ614198B2 (en) Antibodies that bind tgf-alpha and epiregulin
CN113842456B (zh) 一种抗人4-1bb的单克隆抗体制剂及其用途
CN114316046B (zh) 一种稳定的抗体组合物
HK1190410B (en) Antibodies that bind tgf-alpha and epiregulin
CN115181185B (zh) 一种结合ctgf的融合蛋白及其应用
TW202334214A (zh) 抗il-17/vegf雙功能融合蛋白及其用途
US20210009672A1 (en) Methods of treating or preventing liver fibrosis with inhibition of activins a & b
JP6140841B6 (ja) Ｖｅｇｆｒ１抗体についての治療的使用
WO2024165077A1 (zh) 一种包含抗vegfa和vegfc双特异性结合蛋白的药物制剂
CN119548621A (zh) 抗igf-1r抗体或其抗原结合部分在减重中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150324

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160302

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160705

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20161129